stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Free cash flow
Johnson & Johnson's free cash flow for fiscal 2025 was $20.4B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $21.0B. Over the past ten years it has ranged from $16.8B (fiscal 2016) to $23.2B (fiscal 2019); the current reading is higher than 55% of that period. Johnson & Johnson ranks 2nd of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $20.4B | (0.48%) |
| FY2024 | $20.5B | 10.27% |
| FY2023 | $18.6B | 4.95% |
| FY2022 | $17.7B | (13.39%) |
| FY2021 | $20.5B | (0.12%) |
| FY2020 | $20.5B | (11.60%) |
| FY2019 | $23.2B | 6.67% |
| FY2018 | $21.7B | 10.84% |
| FY2017 | $19.6B | 16.66% |
| FY2016 | $16.8B | (14.11%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $6.4B | (13.65%) |
| Jun 2026 | $7.4B | 392.50% |
| Mar 2026 | $1.5B | (74.17%) |
| Dec 2025 | $5.8B | (28.49%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson | $21.0B |
| LLY Eli Lilly and Company compare | $19.7B |
| ABBV AbbVie Inc. compare | $18.9B |
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement